ViroCell Biologics confirms a new agreement to address the worldwide viral vector market for clinical trials.
Read MoreGreat Ormond Street Hospital (GOSH) has partnered with manufacturer ViroCell Biologics in an effort to address the global viral vector manufacturing bottleneck for clinical trials.
Read MoreAs part of the partnership, ViroCell will more than double the UK’s lentivirus vector manufacturing capacity for clinical trials in 2022 and become the first UK CDMO to be able to deliver AAV vectors to the cell and gene therapy markets.
Read MoreInnovation-driven viral vector manufacturer, ViroCell Biologics, and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), have announced a new partnership that aims to dislodge the gene and cell therapy bottleneck.
Read MoreViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.
Read MoreViroCell Biologics and Great Ormond Street Hospital (GOSH) partner to tackle the viral vector manufacturing bottleneck for clinical trials.
Read MoreViroCell Biologics and Great Ormond Street Hospital for Children (GOSH) have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.
Read MoreViroCell Biologics and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) have formed a new partnership to immediately address the global viral vector manufacturing bottleneck for clinical trials.
Read MoreLife sciences firm ViroCell Biologics is working in partnership with Great Ormond Street Hospital (GOSH) to help alleviate a major barrier to progress in clinical trials.
Read MoreViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.
Read MoreViroCell Biologics – David Enloe was appointed to the board of directors of ViroCell and Martin Pule was appointed to the company’s Scientific Advisory Board.
Read MoreViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.
Read MoreViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.
Read MoreViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched.
It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.
Read MoreViroCell will supply viral vectors and genetically modified cells to academic and corporate customers for translational cell and gene therapy entering clinical trials.
Read MoreViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.
Read MoreViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.
Read More